ATE269291T1 - Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren - Google Patents

Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren

Info

Publication number
ATE269291T1
ATE269291T1 AT01926670T AT01926670T ATE269291T1 AT E269291 T1 ATE269291 T1 AT E269291T1 AT 01926670 T AT01926670 T AT 01926670T AT 01926670 T AT01926670 T AT 01926670T AT E269291 T1 ATE269291 T1 AT E269291T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
receptor modulators
selective estrogen
salt form
special salt
Prior art date
Application number
AT01926670T
Other languages
English (en)
Inventor
Gary A Cain
Reginald O Cann
Christopher A Teleha
Denette K Murphy
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE269291T1 publication Critical patent/ATE269291T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01926670T 2000-04-05 2001-04-05 Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren ATE269291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19458000P 2000-04-05 2000-04-05
PCT/US2001/011169 WO2001077055A2 (en) 2000-04-05 2001-04-05 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
ATE269291T1 true ATE269291T1 (de) 2004-07-15

Family

ID=22718126

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926670T ATE269291T1 (de) 2000-04-05 2001-04-05 Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren

Country Status (12)

Country Link
US (1) US6417394B2 (de)
EP (1) EP1268387B1 (de)
JP (1) JP2004507452A (de)
AT (1) ATE269291T1 (de)
AU (2) AU5319101A (de)
CA (1) CA2403263A1 (de)
DE (1) DE60103867T2 (de)
DK (1) DK1268387T3 (de)
ES (1) ES2222988T3 (de)
PT (1) PT1268387E (de)
TR (1) TR200401601T4 (de)
WO (1) WO2001077055A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417169A2 (de) * 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selektive östrogenrezeptormodulatoren
DE602004014806D1 (de) * 2003-10-08 2008-08-14 Smithkline Beecham Corp Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1951217A4 (de) * 2005-11-22 2009-08-12 Smithkline Beecham Corp Chemische verbindungen
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
CA2861066C (en) * 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
WO1999008682A1 (en) * 1997-08-15 1999-02-25 Duke University A method of preventing or treating estrogen-dependent diseases and disorders

Also Published As

Publication number Publication date
CA2403263A1 (en) 2001-10-18
PT1268387E (pt) 2004-09-30
AU5319101A (en) 2001-10-23
TR200401601T4 (tr) 2004-08-23
ES2222988T3 (es) 2005-02-16
WO2001077055A2 (en) 2001-10-18
JP2004507452A (ja) 2004-03-11
EP1268387A2 (de) 2003-01-02
AU2001253191B2 (en) 2006-03-02
DE60103867T2 (de) 2005-06-30
EP1268387B1 (de) 2004-06-16
WO2001077055A3 (en) 2002-05-30
DE60103867D1 (de) 2004-07-22
US6417394B2 (en) 2002-07-09
US20020004496A1 (en) 2002-01-10
DK1268387T3 (da) 2004-10-18

Similar Documents

Publication Publication Date Title
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
ATE374609T1 (de) Synthese von 4-aminothalidomid enantiomeren
DE69929345D1 (de) Subtituierte isoxazole derivate als estrogen rezeptor modulatore
HK1052500A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
NO20031687L (no) Veksthormonsekretagoger
MXPA03001982A (es) Amino-aza-cicloalcanos sustituidos utiles contra la malaria.
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2003016270A3 (en) Selective estrogen receptor modulators
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
DK1124842T3 (da) Betulinsyrederivater anvendelige til behandling af neuroektodermale tumorer
ME00428B (me) 5-hlor0-3-(4-metansulfonilfenil)-6'-metil-(2,3')bipiridinil u čistom kristalnom obliku i postupak sinteza
DE60103867D1 (de) Spezielle salzform von triphenylethylenederivaten als selektive östrogenrezeptormodulatoren
DE602006005254D1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden
ATE276995T1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
MXPA01008347A (es) Compuestos quimicos.
AP2002002641A0 (en) Estrogen agonist metabolites.
EA200600330A1 (ru) Замещённые имидазопиримидины для предупреждения и лечения рака
RS56004A (en) Triazolo-quinolin derivatives useful as adenosine receptor ligands
GB0425548D0 (en) Radiolabelled ligands
SG85165A1 (en) Alpha, beta-unsaturated ketones
WO2004087673A3 (en) Migrastatin analogs and uses thereof
ATE257831T1 (de) Synthese von wasserlöslischem 9-dihydroplacitaxel derivate aus 9-dihydro-13-acetylbacchatin iii
WO2002038534A3 (en) Substituted alkyldiamines as inhibitors of plasmepsin or related proteases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1268387

Country of ref document: EP

REN Ceased due to non-payment of the annual fee